Danish biotech firm Alcolase is developing a new supplement to assist individuals with a genetic inability to process alcohol. The product aims to break down ethanol in the stomach before it reaches the bloodstream, potentially mitigating severe physical reactions and long-term health risks.
The fat-shelled enzymes targeting the stomach
The proposed Alcolase supplement functions by introducing man-made enzymes directly into the digestive tract to neutralize alcohol upon ingestion . As reported by the source, the supplement will be available as either a liquid or a gel contained within a capsule. To survive the harsh, acidic environment of the human stomach, these enzymes are protected by a specialized outer layer of fats.
This fatty shell is designed to be permeable to ethanol, allowing the alcohol to pass through so the enzymes can immediately begin converting it into harmless by-products. Once these by-products are created, they are intended to be flushed out of the body as waste. The company hopes to initiate human testing within the next few months to validate this mechanism.
The 1-in-3 statistic facing East Asian populations
The development of this supplement addresses a significant global health disparity related to the ALDH2 gene. This specific gene is responsible for producing the enzyme that clears acetaldehyde—a toxic substance—from the body. For those with a genetic deficiency, even minimal alcohol consumption can trigger rapid heart rates, nausea, headaches,and intense facial flushing.
The prevalence of this deficiency varies significantly by geography. According to the report, roughly one in three people in countries such as China, Japan, and Korea are affected by this genetic variant. In contrast, the deficiency appears in fewer than 5 percent of Western populations. This suggests that the Alcolase supplement could have a massive market, particularly in East Asian regions where the physiological response to alcohol is a common biological reality.
A 3x higher risk of oesophageal cancer
Beyond the immediate discomfort of a hangover or flushing, the ALDH2 deficiency carries heavy long-term medical implications. Because the body cannot efficiently clear acetaldehyde, the toxin accumulates and causes cellular damage. The report cites a 2021 study from researchers at Chonnam National University in South Korea, which found that adults with this defective gene were more than three times as likely to develop oesophageal cancer compared to those without the fault.
The risks extend to other forms of malignancy as well. A separate 2021 study conducted at Seoul National University Hospital found that light to moderate drinkers with the genetic deficiency faced a 20 percent higher risk of stomach cancer. For heavy drinkers carrying the variant, that risk more than doubles. By intercepting the alcohol in the stomach, Alcolase aims to prevent these toxins from ever reaching the organs responsible for processing them.
The missing data from human clinical trials
While the science behind the ALDH2 gene is well-established, the efficacy of the Alcolase supplement remains unproven in living subjects . As the source indicates, the product has yet to undergo human testing, leaving several critical questions unanswered. It is currently unknown if the fat-based delivery system will work consistently across different diets or if the enzyme conversion rate will be high enough to prevent the "buzz" or intoxication entirely.
Furthermore, there is a lack of clarity regarding how this supplement compares to the various over-the-counter products already marketed online. Andrew Misell, a spokesman for the charity Alcohol Change UK, noted that while many products claim to assist with acetaldehyde breakdown, none have been verified through rigorous clinical trials. Until Alcolase releases human trial data, the claim that it can safely and effectively prevent the toxic buildup of acetaldehyde remains speculative.
Comments 0